

The Green Organic Dutchman Holdings Ltd.
Unaudited Interim Condensed Consolidated Financial Statements
For the three and six months ended June 30, 2020 and June 30, 2019

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited)

(expressed in thousands of Canadian dollars, except common shares outstanding)

	Notes	As at June 30, 2020	As at December 31, 2019
ASSETS			
Current assets			
Cash and cash equivalents		,	
Restricted cash	15[a]	219	8,578
Refundable sales taxes receivable		2,546	8,553
Trade receivables	16	2,656	1,488
Biological assets	7	2,336	2,771
Inventories	8	13,854	8,268
Prepaid expenses and deposits		7,873	8,382
Due from related parties	10	-	699
Other current assets	10	627	534
Deferred financing costs	S	1,385 50,273	\$\frac{1,324}{68,166}
Non-current assets	a a	50,275	\$ 08,100
Property, plant and equipment	5	208,807	237,033
Intangible assets	6	10,729	12,019
Goodwill	6	8,481	8,101
Investments in associates	9	2,194	4,918
Other assets	10, 15[a]	12,393	11,944
Cities disselle	10, 15[4]	12,000	
Total assets	9	292,877	\$ 342,181
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities			
Current portion of accounts payable and accrued liabilities	\$	32,672	\$ 52,074
Income tax payable		_	39
Deferred revenue		135	
Due to related parties		279	_
Current portion of loans	4	28,626	524
Current portion of lease liabilities	11	858	590
		62,570	53,227
Non-current liabilities			
Loans	4	9,307	16,909
Lease liabilities	11	4,229	2,955
Accrued liabilities		1,710	
Contingent consideration		101	462
Deferred tax liability		752	1,028
		16,099	21,354
Total liabilities	9	78,669	\$ 74,581
Shareholders' equity			
Share capital	12	447,830	428,651
Contributed surplus	13	104,326	95,763
Deficit Deficit	13	(336,824)	
Reserve for foreign currency translations		(164)	
Total Shareholders' Equity attributed to The Green Organic Dutchman		(104)	(2,241)
Holdings Ltd.	5	215,168	\$ 268,155
Non-controlling interests	,	(960)	
Total Shareholders' Equity		214,208	267,600
Total Liabilities and Shareholders' Equity	S	292,877	
4		,	,
Total number of common shares outstanding		384,653,284	312,733,244
	2		
Going Concern	2		
Commitments and contingencies	15		
Events after the reporting period	2, 20		

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (Unaudited)

(expressed in thousands of Canadian Dollars, except per share amounts)

	Notes		For the three mo June 30, 2020	June 30, 2019	_	June 30, 2020	June 30, 2019
Revenue		\$	4,825 \$	2,896	\$	7,884 \$	5,301
Excise duties		Ψ	(403)	2,070	Ψ	(531)	
Net revenue		_	4,422	2,896		7,353	5,301
Cost of sales related to inventory production			4,028	944		5,944	1,927
Cost of sales related to inventory production Cost of sales related to business combination fair value			4,020	744		3,744	1,927
adjustments to inventories			_	_		_	270
Gross profit before change in fair value of biological assets		-	394	1,952		1,409	3,104
Realized fair value adjustment on sale of inventory			(1,821)				
3	7		2,753	(5) 10		(2,366) 3,989	(5 225
Unrealized gain on changes in fair value of biological assets	/	Φ -			σ-		
Gross profit		\$_	1,326 \$	1,957	\$_	3,032 \$	3,324
Operating expenses							
Sales and marketing expenses		\$	2,240 \$	3,930	\$	4,703 \$	6,926
Research and development expenses			319	586		839	1,022
General and administrative expenses			5,710	8,687		15,502	17,366
Share based compensation	13		1,657	4,433		4,127	7,852
Depreciation and amortization	5, 6		1,281	738		3,000	1,299
Total operating expenses	19	\$	11,207 \$	18,374	\$	28,171 \$	34,465
Loss from operations			(9,881)	(16,417)		(25,139)	(31,141
Loss from operations			(2,001)	(10,417)		(23,137)	(31,141
Foreign exchange gain (loss)	16[c]		785	(315)		(1,729)	(475
Finance costs			(877)	(143)		(1,016)	(232
Accretion expense	4		(250)	_		(250)	_
Modification of debt	4		(33)	_		(33)	_
Finance income			98	869		269	2,055
Strategic business initiatives			_	(606)		_	(606
Share of loss on investments in associates	9		_	(230)		(148)	(452
Revaluation of contingent consideration			92	175		361	200
Gain on disposal of assets	5		76	_		44	_
Impairment of investment in associates	9		_	_		(3,082)	_
Impairment charge for non-financial assets	5, 6	_		_		(52,765)	_
Loss before income taxes			(0.000)	(16.667)		(02.400)	(20.651
			(9,990)	(16,667)		(83,488)	(30,651
Current income tax recovery (expense)			215	(93)		277	(214
Deferred income tax recovery		_	215	157	_		171
Net loss		\$ =	(9,775)\$	(16,603)	\$ =	(83,211) \$	(30,694
Other comprehensive (income)/loss							
Foreign currency translation (income)/loss			471	156		(1,369)	1,458
Foreign currency translation (income)/loss on equity method	0					, ,	
investment	9		(202)	547		(708)	595
Comprehensive loss		\$ _	(10,044)\$	(17,306)	\$	(81,134)\$	(32,747
Net loss attributable to:							
The Green Organic Dutchman Holdings Ltd.			(9,655)	(16,440)		(82,806)	(30,447
Non-controlling interests			(120)	(163)		(405)	(247
Comprehensive loss attributable to:							
The Green Organic Dutchman Holdings Ltd.			(9,924)	(17,143)		(80,729)	(32,500
Non-controlling interests			(120)	(163)		(405)	(247
Non-controlling interests							
Non-controlling interests							
Basic and diluted net loss per share		\$	(0.03) \$	(0.06)	\$	(0.25) \$	(0.11

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

The Green Organic Dutchman Holdings Ltd.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

		(expressed in thousands of Canadian Dollars, except number of shares)
		of s
		nber
		nnu
		excepi
		ars,
		Doll
		dian
		ana
		ofC
		$z_{\mathcal{E}}$
		ısanı
		0
)		th
)	$\overline{}$	in
	þa	a
ĺ	Unaudite	se
	nc	es.
	п	M
	\mathcal{C}	(ex

		Share Capital	pital			Contributed Surplus	ed Surplus						
										Reserve for			
				Reserve for		Other			Total	foreign		Non-	
	N 2400	Common	*	share based	based Reserve for contributed	contributed	Escrowed		Contributed		Accumulated Controlling	Controlling	T. 401
	Notes	Suares	Amount	payments	warrants	surbins	snare units	De Issued	surbins	translations	dencit	Interests	I Otal
		#	S	S	ss	S	S	S	ss	↔	S	S	S
Balance at December 31, 2019		312,733,244	428,651	22,247	64,415	1,129	7,972	I	95,763	(2,241)	(254,018)	(555)	267,600
Share based compensation	13[a], 13[c]	I	15	2,205	I	I	I	I	2,205	I	I	I	2,220
Exercise of stock options	13[a]	847,600	763	(339)	I	I	I	I	(339)	I	I	I	424
Exercise of warrants	13[b]	200	1	I	I	I	I	I	•	I	I	I	
Expiry of options		I	I	(272)	I	272	I	I	1	I	I	I	ı
RSU exercised during period	13[c]	27,174	75	(75)	I	I	I	I	(75)	I	I	I	•
Shares to be issued	12	I	I	I	I	I	I	1,876	1,876	I	I	I	1,876
Comprehensive loss for period		I	l	I	I	I	I	I	-	2,346	(73,151)	(285)	(71,090)
Balance at March 31, 2020		313,608,518	429,505	23,766	64,415	1,401	7,972	1,876	99,430	105	(327,169)	(840)	201,031
Bought deal offerings	12	63,661,700	16,220	I	4,533	I	I	I	4,533	I	I	l	20,753
Share based compensation	13[a], 13[c]	I	∞	1,649	I	I	ı	I	1,649	I	I	I	1,657
Warrants issued in connection with debt	13[a]	I	I	I	621	I	I	I	621	I	I	I	621
Exercise of warrants	13[b]	200,000	221	I	(31)	I	I	I	(31)	I	I	I	190
Expiry of warrants		I	I	I	(8,150)	8,150	I	I	1	I	I	I	•
Expiry of options		I	I	(648)	I	648	I	I	•	I	I	I	•
Convertible Shares Issued	12	24,691	I	I	I	I	I	I	1	I	I	I	•
Transfer from Shares to be issued	12	6,858,375	1,876	I	I	I	I	(1,876)	(1,876)	I	l	l	ı
Comprehensive loss for period		I	I	I	I	I	I	I	'	(269)	(9,655)	(120)	(10,044)
Balance at June 30, 2020		384,653,284	447,830	24,767	61,388	10,199	7,972	-	104,326	(164)	(336,824)	(096)	214,208

		Share Capital	apital		Co	Contributed Surplus	Ins					
		Common		Reserve for share hased	Reserve for	Other	Escrowed	Total Contributed	Reserve for foreign	Accumulated deficit	Non- Controlling	
	Notes	Shares	Amount	payments	warrants	surplus	share units	surplus	translations		Interests	Total
		#	s	s	s	÷	s	÷	s	se	s	se
Balance at December 31, 2018		269,976,624	392,068	8,053	62,801	1,111	7,972	79,937	513	(58,823)	[413,695
Effect of adoption of IFRS 16		I	1	1	I	1	1	1	I	(40)	I	(40)
Balance at January 1, 2019		269,976,624	392,068	8,053	62,801	1,111	7,972	79,937	513	(58,863)		413,655
Stock based compensation	13[a], 13[c]	I	38	3,381				3,381		I	I	3,419
Exercise of stock options		134,800	176	(73)		1	1	(73)		l		103
Exercise of warrants	13[b]	4,264,354	10,937	1	(1,749)	I	I	(1,749)	I	I	I	9,188
Cancellation of shares		(5,880)		1	1	1	1		1	l	I	•
Contribution from non-controlling interest		I	1	I	1	1	1	I	1	I	40	40
Net loss and comprehensive loss		1		1	1	1	1		(1,350)	(14,007)	(84)	(15,441)
Balance at March 31, 2019		274,369,898	403,219	11,361	61,052	1,111	7,972	81,496	(837)	(72,870)	(44)	410,964
Stock based compensation	13[a], 13[c]	I	26	4,407		l	l	4,407		I		4,433
Exercise of stock options		235,133	351	(135)	1	1	1	(135)	1	I	I	216
Exercise of warrants	13[b]	841,057	2,408	1	(390)	1	1	(390)	1	l	l	2,018
Expiry of warrants		1	1	1	(10)	10	1	1	1	1	I	1
Issuance of convertible units		1		300	1	l	l	300	1	1	l	300
Comprehensive loss		1				1	1	1	(703)	(16,440)	(163)	(17,306)
Balance at June 30, 2019		275,446,088	406,004	15,933	60,652	1,121	7,972	85,678	(1,540)	(89,310)	(207)	400,625

An unlimited number of common shares are authorized for issue.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(expressed in thousands of Canadian dollars)

	Notes	For the three solution June 30, 2020	months ended June 30, 2019	For the six mo	onths ended June 30, 2019
OPERATING ACTIVITIES					
Net loss	9	(9,775) \$	(16,603) \$	(83,211) \$	(30,694)
Items not affecting cash:					
Impairment of property, plant and equipment	5	_	_	51,725	_
Impairment of investment in associates	9	_	_	3,082	_
Impairment of intangible assets	6	_	_	1,040	_
Share based compensation	13	1,657	4,733	4,127	8,152
Depreciation of property, plant and equipment	5	958	422	2,221	684
Amortization of intangible assets	6	323	316	779	615
Realized fair value adjustment on sale of inventory		1,821	_	2,366	_
Unrealized gain on change in fair value of biological assets	7	(2,753)	(10)	(3,989)	(225)
Accretion	4	250	_	250	_
Share of loss on investments in associates	9	_	230	148	452
Revaluation of contingent consideration		(92)	(175)	(361)	(200)
Loss (gain) on disposals of property, plant and equipment	5	(76)	29	(44)	36
Debt modification	4	33	_	33	_
Deferred financing costs expensed		276	_	276	_
Current income tax recovery expense		_	93	_	214
Deferred income tax recovery		(215)	(157)	(277)	(171)
Income taxes paid		(14)	(26)	(14)	(26)
Changes in non-cash operating working capital items	14	(678)	(13,378)	467	(24,513)
Net cash used in operating activities	\$	(8,285) \$	(24,526) \$	(21,382) \$	(45,676)
INVESTING ACTIVITIES					
Additions to property, plant and equipment	5	(10,574)	(77,274)	(36,109)	(103,270)
Transfer from (to) restricted cash	15[a]	_	(4,000)	8,359	(4,000)
Advances from (to) related parties, net of repayments		727	11	978	(98)
Net cash outflow on other investment		_	(1,434)	_	(1,434)
Additions to intangible assets	6	(225)	(957)	(225)	(1,870)
Net cash used in investing activities	\$	(10,072) \$	(83,654) \$	(26,997) \$	(110,672)
FINANCING ACTIVITIES					
Proceeds from issuance of shares and warrants, net of share issue costs	12	20,753	_	20,753	_
Proceeds from issuance of debt, net of issue costs	4	12,351		19,009	
Proceeds from the exercise of stock options and warrants	12	190	2,234	615	11,525
Interest received	12	20	2,014	144	2,388
Interest paid on lease liabilities	11	(115)	(61)	(248)	(61)
Interest paid on debt	4	(1,101)	(01)	(1,621)	(01)
Principal payments of lease liabilities	11	(87)	(164)	(1,021)	(164)
Repayments of short-term loans	11	(67)	15	(109)	(156)
Loan receivable			(1,451)		(1,451)
Capital contributed by non-controlling interest			(1,431)		40
Net cash provided by financing activities	9	32,011 \$	2,587 \$	38,483 \$	12,121
Net cash outflow	9			(9,896) \$	(144,227)
Net effects of foreign exchange		276	(120)	1,104	(607)
Cash, beginning of period		4,847	174,428	27,569	213,549
Cash and cash equivalents, end of period	\$	18,777 \$	68,715 \$	18,777 \$	68,715

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

1. NATURE OF ACTIVITIES

The Green Organic Dutchman Holdings Ltd. ("TGODH" or the "Company") was incorporated on November 16, 2016, under the *Canada Business Corporations Act* ("CBCA"). The Company is a reporting issuer domiciled in Canada whose shares and certain warrants are publicly traded on the Toronto Stock Exchange ("TSX") under the symbol "TGOD" and on the OTCQX under the symbol "TGODF". The Company's registered and head office is located at 6205 Airport Road, Building A – Suite 200, Mississauga, ON, L4V 1E3. These unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2020 and 2019 ("Interim Consolidated Financial Statements") include the financial statements of The Green Organic Dutchman Holdings Ltd. and its subsidiaries from the date the Company gained control of each subsidiary.

The Company's wholly-owned subsidiaries, The Green Organic Dutchman Ltd. ("TGOD") and Medican Organic Inc. ("Medican") are licensed producers under the *Cannabis Act* (Canada) and hold various licences to produce cannabis plants, cannabis plant seeds, dried cannabis, fresh cannabis, cannabis oils, cannabis topicals, cannabis extracts and edible cannabis and to sell such cannabis products within Canada to provincially authorized retailers or distributors and federally licensed entities. The Company has built a cultivation facility near Hamilton, Ontario and is building another facility located in Valleyfield, Québec.

In addition to its Canadian operations, the Company, through its subsidiaries and strategic investments, is pursuing an international growth strategy, including interests in a hemp cultivation and extraction business based in Poland. The Company has also formed a strategic partnership for the distribution of cannabis and hemp-derived medical products in Mexico and joint ventures in Denmark for producing organic medical cannabis and developing cannabis genetics. It has also established a company in Germany for the distribution of medical cannabis.

The outbreak of the novel strain of the coronavirus, SARS-COV-2 ("COVID-19"), and its eventual declaration as a pandemic by the World Health Organization ("WHO") on March 11, 2020 has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures have caused material disruption to businesses globally resulting in an economic slowdown. The Company rapidly implemented strategic measures to protect its global workforce from COVID-19 and endeavouring to mitigate any long-term impacts of the pandemic on its business which remain unknown.

2. BASIS OF PRESENTATION

[i] Going concern

These Interim Consolidated Financial Statements have been prepared on a going concern basis which presumes that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the normal course of its operations.

As of June 30, 2020, the Company had negative working capital of \$12,297 (December 31, 2019 – positive working capital of \$14,939) and an accumulated deficit of \$336,824 (December 31, 2019 - \$254,018). During the six months ended June 30, 2020, the Company used cash in operating activities of \$21,382 (six months ended June 30, 2019 - \$45,676) resulting primarily from the net loss of \$83,211 (six months ended June 30, 2019 - \$30,694) offset by items not affecting cash such as depreciation, amortization, stock based compensation and impairment charges of \$62,974 (six months ended June 30, 2019 - \$9,151). The Company has insufficient cash to fund its planned operations, including debt repayments for the next twelve months (see note 4). The Company's ability to continue as a going concern is dependent upon its ability to generate sufficient revenues and positive cash flows from its operating activities to meet its obligations.

The Company may need to reschedule its current debt obligations or obtain further financing in the form of debt, equity or a combination thereof for the next twelve months. There can be no assurance that the existing debt obligations will be rescheduled or that additional funding will be available to the Company, or, if available, that this financing will be on acceptable terms. If existing debt obligations are not rescheduled or adequate financing is not available, the Company may be required to delay or reduce the scope of any or all of its projects. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

These Interim Consolidated Financial Statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. Should the Company be unable to generate sufficient cash flow from financing and operating activities, the carrying value of the Company's assets could be subject to material adjustments and other

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

adjustments may be necessary to these financial statements should such events impair the Company's ability to continue as a going concern.

Subsequent to June 30, 2020, the Company obtained gross debt proceeds of \$3,000 on July 7, 2020 in accordance with the modification of its Revolving Credit Facility (as defined in Note 4), refer to Notes 4 and 20.

[ii] Interim Financial Reporting

These Interim Consolidated Financial Statements have been prepared in accordance with International Accounting Standard ("IAS") 34, "Interim Financial Reporting" as issued by the International Accounting Standards Board ("IASB"). The same accounting policies and methods of computation were followed in the preparation of these Interim Consolidated Financial Statements as those disclosed in the Company's annual audited consolidated financial statements for the year ended December 31, 2019.

These Interim Consolidated Financial Statements do not include all of the information required for full annual consolidated financial statements and accordingly should be read in conjunction with the annual audited consolidated financial statements for the year ended December 31, 2019 which are made available on SEDAR at www.sedar.com.

These Interim Consolidated Financial Statements were approved by the Board of Directors of the Company and authorized for issue by the Board of Directors of the Company on August 12, 2020.

3. SIGNIFICANT ACCOUNTING POLICIES

The preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, income and expenses, consistent with those disclosed in the 2019 annual consolidated financial statements and as described in these condensed consolidated interim financial statements. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Estimates are based on historical experience and other assumptions that are considered reasonable in the circumstances. The actual amount or values may vary in certain instances from the assumptions and estimates made. Changes will be recorded, with corresponding effect in profit or loss, when, and if, better information is obtained.

(a) Measurement Uncertainty

The Company continues to monitor the evolution of the COVID-19 pandemic. The extent to which the COVID-19 pandemic may impact the Company's business and activities will depend on future developments which remain highly uncertain and cannot be predicted with confidence, such as the spread and severity of the disease, the duration of the outbreak including any possible resurgence, and actions taken by authorities to control the spread of the virus, the impact of the pandemic on spending, and the ability or willingness of suppliers and vendors to provide products and services.

Any of these developments, and others, could have a material adverse effect on the Company's business, affairs, operations, results of operations, financial condition, liquidity, availability of credit and foreign exchange exposure. In addition, because of the severity and global nature of the COVID-19 pandemic, it is possible that estimates in the Company's financial statements could change in the near term and the effect of any such changes could be material, which could result in, among other things, an impairment of non-current assets and a change in the expected credit losses on accounts receivable. The Company is constantly evaluating the situation and monitoring any impacts or potential impacts on its business.

(b) Government Grants

The Company applied for and received government grants under the Canadian Emergency Wage Subsidy ("CEWS") provided by the Government of Canada as a result of the COVID-19 pandemic. The Company made an accounting policy choice under *IAS 20 - Government Grants* to record and present the grants net against the associated salary expenses for which it was subsidizing.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

4. LOANS

The following tables illustrate the continuity schedule and presentation of the Company's loans:

	 June 30, 2020	December 31, 2019
Opening Balance	\$ 17,433 \$	688
Additions	21,658	21,042
Deferred financing fee	(2,427)	(3,425)
Residual fair value of equity portion	(506)	(758)
Accretion	1,757	50
Loss on modification of loans	33	_
Principal payments	_	(123)
Effects of movements in foreign exchange	 (15)	(41)
Ending Balance	\$ 37,933 \$	17,433

	June 30, 2020	December 31, 2019
Loans	\$ 37,933	\$ 17,433
Current portion	 (28,626)	(524)
Long term portion	\$ 9,307	\$ 16,909
		_
Senior Loan	\$ 28,626	\$ 16,909
Revolver Loan	8,798	_
HemPoland Loan	509	524
	\$ 37,933	\$ 17,433

Senior secured credit facility ("Senior Loan")

On December 24, 2019, the Company closed a senior secured first lien credit facility (the "Senior Loan") with a commercial lender. The first tranche of the Senior Loan for gross proceeds of \$21,042 was advanced by the lender upon closing at a thirteen percent (13%) rate of interest. Per the Senior Loan agreement, there are no scheduled principal repayments for the first twelve months of the term of the Senior Loan and after which the Company is required to make monthly principal repayments commencing on January 1, 2021 plus interest, with the remaining unpaid balance due upon maturity on June 21, 2021. During the six months ended June 30, 2020, the lender advanced the remaining \$6,658 of the first tranche. The second tranche of the Senior Loan included an accordion feature, which made available up to an additional \$15,000 which could be advanced upon the achievement by the Company of certain operational milestones. Both tranches of the Senior Loan mature on June 21, 2021. The Company may repay the Senior Loan at any time with a 2% penalty on the outstanding principal of the Senior Loan. The Senior Loan possesses several covenants which the Company has met as at June 30, 2020.

On April 13, 2020, the Company executed an amendment with the lender of the Senior Loan on the \$15,000 accordion feature that made the \$5,000 of the accordion available upon the Company closing an equity financing which was achieved on April 27, 2020 (see note 12). The Company received gross proceeds from the accordion loan of \$5,000 on April 27, 2020. In addition, on April 27, 2020 a total of 1,500,000 warrants were issued to the lender of the Senior Loan exercisable at \$0.39 for 36 months from the date of issuance.

Revolving credit facility ("Revolver Loan")

On April 22, 2020, the Company closed a revolving credit facility secured second lien credit facility (the "Revolver Loan") with a commercial lender for gross proceeds of up to \$30,000 of which \$10,000 was funded on April 22, 2020. The Revolver Loan is secured by a second lien over the assets of the Company with a first lien over certain eligible inventory and trade receivables. If the accounts receivable balance eligible for collateral increases, additional credit is available to the Company up to a maximum of an additional \$20,000. The Revolver Loan originally matured on April 1, 2021, subject to renewal for an additional year. In connection with the Revolver Loan, the Company issued the lender of the Revolver Loan 3,000,000 common share purchase warrants of the Company exercisable for a period of 36 months following the date of issuance at a price of \$0.39 in exchange for one common share of the Company. A finder's fee of \$450 was paid to the lender of the Company's Senior Loan in connection with the closing of the initial proceeds of the Revolver Loan.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

On May 27, 2020, the Company executed an amendment with the lender of the Revolver Loan which extended the original term by six months to October 1, 2021 and allowed the Company to receive \$3,000 in gross proceeds from the \$20,000 revolving component subject to the same terms of the first \$10,000 previously advanced by this lender. In consideration of this, a total of 500,000 warrants were issued on May 22, 2020 to this lender exercisable at \$0.50 for 48 months from the date of issuance. The Company received this \$3,000 on July 7, 2020, see Note 20 – Events after the reporting period.

HemPoland Loan

The Company assumed a loan payable on certain premises in Poland ("HemPoland Loan") on the acquisition of its wholly owned subsidiary HemPoland on October 1, 2018, of which approximately \$509 remained outstanding as at June 30, 2020 (December 31, 2019 - \$524). During the six months ended June 30, 2020, the Company received an extension to defer payment on the outstanding balance to December 31, 2021; therefore, the loan payable was reclassified to the long-term portion as at June 30, 2020.

The Green Organic Dutchman Holdings Ltd.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2020 AND 2019 (Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

5. PROPERTY, PLANT AND EQUIPMENT

			Furniture											
			and	Pre	Production	Building	Computer	Į.		Const	Construction	Right-of-use	nse	
Cost:	Land	Buildings	fixtures	ba	equipment	improvements	equipment		Automobiles	in pr	in progress	assets		Total
Balance, December 31, 2019	\$ 2,683	\$ 56,480	\$ 265	s S	15,674	\$ 710	\$ 1,337	\$ 7	551	\$	277,646	\$	4,154	\$ 359,500
Transfers	I	279	237	7	38	I	•	ı	∞		(295)		ı	I
Additions	l	I	13	3	116	I	•	ı	37		17,377	2,	2,403	19,946
Disposals	I	I	I		(27)	I	•	ı	(28)		4		(21)	(80)
Effects of movements in foreign exchange and other	I	(8))	(1)	25	I	•	ı	(2)		(1)		(8)	S
Balance, March 31, 2020	\$ 2,683	\$ 56,751	\$ 514	8	15,826	\$ 710	\$ 1,337	8	999	59	294,456	8 6,	6,528	\$ 379,371
Transfers	I	78	l		7	I	•	ı	I		(93)		∞	I
Additions	I	I	1		211	I		7	65		6,021		ı	6,299
Disposals	I	l	I		9	(12)	•	ı	(113)		(20)		(72)	(223)
Effects of movements in foreign exchange and other	I	11		7	1	I	•	,	1		(283)		10	(258)
Balance, June 30, 2020	\$ 2,683	\$ 56,840	\$ 516	<u>& </u> •	16,039	869 \$	\$ 1,339	ଛା ୫	519	9	300,081	8	6,474	\$ 385,189
Accumulated depreciation and impairment:														
Balance, December 31, 2019	∻	\$ 19,559	\$ 139	\$	5,730	\$ 401	\$	673 \$	261	69	95,062	€	642	\$ 122,467
Depreciation	l	456	1	10	491	6	4,	55	33		I		209	1,263
Disposals	I	J	I		9)	I	•	ı	(21)		I		(21)	(48)
Impairment	I	7,521	2	25	1,713	36	12	128	20		42,282		ı	51,725
Effects of movements in foreign exchange and other	1	I	1		(2)	I	•		ı		I		(4)	(9)
Balance, March 31, 2020	9	\$ 27,536	\$ 174	8	7,926	\$ 446	\$ 856	99	293	∽	137,344	\$	826	\$ 175,401
Depreciation	I	363	11	1	389	7	4	42	64		I		217	1,093
Disposals	I	I	I		(S)	(1)	•	ı	(63)		I		(20)	(119)
Effects of movements in foreign exchange and other	I	I	I		8	1			I		I		4	7
Balance, June 30, 2020	 	\$ 27,899	\$ 185	8	8,313	\$ 452	868 \$	 	294	€9	137,344	\$	8 766	\$ 176,382
Net book value, June 30, 2020	\$ 2,683	\$ 28,941	\$ 331	8	7,726	\$ 246	\$ 441	 	225	so.	162,737	\$	5,477	\$ 208,807

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

Impairment of property, plant and equipment

The Company performs tests for impairment of its property, plant and equipment, a non-financial asset, when there are indicators of impairment. The following factors were identified as impairment indicators during the six months ended June 30, 2020:

- i. Economic environment: On March 11, 2020, the WHO declared the COVID-19 outbreak a global health pandemic which subsequently has resulted in a change of expected outcomes initially forecasted by management;
- ii. Change in strategic plans: On March 27, 2020, the Company temporarily ceased construction activities and temporarily laid off the majority of its staff located at the Quebec Facility due to multiple factors, most particularly the COVID pandemic, affecting planned production output.

As a result of an impairment assessment at March 31, 2020, the cannabis related activities from production in Canada ("the Canadian CGU") as part of the North American segment, yielded a lower recoverable amount in comparison to its applicable carrying values considering different scenarios that have been probability weighted due to economic uncertainty arising from the COVID-19 pandemic. The recoverable amount of this CGU was based on its value in use, determined by discounting the future cash flows to be generated from the continuing use of the CGU using level 3 inputs. As at March 31, 2020, the carrying amount of the CGU was determined to be higher than its recoverable amount based on value in use of \$196,600 for which a non-cash impairment charge of \$52,765 was recognized during the six months ended June 30, 2020. The Company did not record any impairment charges for its CGUs for the three months ended June 30, 2020 (three and six months ended June 30, 2019 - \$nil).

The significant assumptions applied in the determination of the recoverable amount are described as follows:

- iii. Cash flows: Estimated cash flows were projected based on industry and market trends in addition to the Company's own internal sources which included estimates for price compression and industry growth. The forecasts were extended to a total of five years (and a terminal period);
- iv. Terminal value growth rate: A long-term growth rate has been determined as the lower of the nominal gross domestic product rate for the country in which the CGU operates and the long-term compound annual growth rate estimated by management. The terminate value growth rate used by management was calculated as 2%;
- v. Discount rate: The discount rate is based on the Company's weighted average cost of capital ("WACC") based on the Company's cost of capital in which the Company's cost of equity and cost of debt are proportionately weighted. The inputs into the WACC are based on the Company's specific borrowing rate, over 10-year government bonds issued by the government in the relevant market and in the same currency as the cash flows, adjusted for risk premium to reflect both the increased risk of investing in equities generally and the unsystematic risk on the specified CGU. The discount rate calculated and used by management in calculating the recoverable amount tested for impairment as at March 31, 2020 was 16.5%.

The non-cash impairment charge was allocated pro rata on the basis of the carrying amount of each non-financial asset, excluding biological assets and inventories, in the CGU. The non-cash impairment charges specific to property, plant and equipment for the three and six months ended June 30, 2020 was \$nil and \$51,725, respectively (three and six months ended June 30, 2019 - \$nil). Refer to Note 6 for non-cash impairment charge of intangible assets.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

6. INTANGIBLE ASSETS AND GOODWILL

A continuity of the intangible assets and goodwill is as follows:

	C	lealth anada icence		chnology icences	W	/ebsite_		stribution Channels	В	rands_	ac	Other equired rights	<u>_</u> G	oodwill		Total
Cost: Balance, December 31, 2019	\$	5,870	\$	2,872	C	400	s	5,500	\$	982	S	1,256	\$	10,108	S	26,988
Additions	Э	5,670	Э	2,072	\$	400	Þ	5,500	Э	962	Þ	1,250	Ф	10,100	Ф	20,900
Effect of movements in foreign exchange		_		21		_		358		64		80		526		1,049
Balance, March 31, 2020	\$	5,870	\$	2,893	\$	400	\$	5,858	\$	1,046	\$	1,336	\$	10,634	\$	28,037
Additions		_		225		_		_		_		_		_		225
Effect of movements in foreign exchange				1				(100)		(18)		(22)		(146)		(285)
Balance, June 30, 2020	\$	5,870	\$	3,119	\$	400	\$	5,758	\$	1,028	\$	1,314	\$	10,488	\$	27,977
Accumulated amortization and impairment:																
Balance, December 31, 2019	\$	2,596	\$	1.035	S	159	S	491	\$	88	S	492	S	2,007	S	6,868
Amortization for the period	Ψ	48	Ψ	182	Ψ	11	Ψ	100	Ψ	18	Ψ	97	Ψ		Ψ	456
Impairment		685		306		49		_		_		_		_		1,040
Effect of movements in foreign exchange		_		22		_		37		7		36		_		102
Balance, March 31, 2020	\$	3,329	\$	1,545	\$	219	\$	628	\$	113	\$	625	\$	2,007	\$	8,466
Amortization for the period		38		55		9		103		18		100		_		323
Effect of movements in foreign exchange		_		1		_		(11)		(2)		(10)		_		(22)
Balance, June 30, 2020	\$	3,367	\$	1,601	\$	228	\$	720	\$	129	\$	715	\$	2,007	\$	8,767
Net book value, June 30, 2020	\$	2,503	\$	1,518	\$	172	\$	5,038	\$	899	\$	599	\$	8,481	\$	19,210

Impairment of intangible assets

During the six months ended June 30, 2020, the Company recognized non-cash impairment charges for intangible assets within its Canadian CGU as described in Note 5, of which \$1,040 related to intangible assets (six months ended June 30, 2019 - \$nil). The Company's did not record any impairment charges for the three months ended June 30, 2020 (three months ended June 30, 2019 - \$nil).

7. BIOLOGICAL ASSETS

As at June 30, 2020, the Company's biological assets consisted of cannabis seeds and cannabis plants. The continuity of the Company's biological assets is as follows:

	Capi	italized cost	Biological asset fair value adjustment	Amount
Balance, January 1, 2019		265	130	395
Purchase of seeds		12	_	12
Unrealized gain on changes in fair value of biological assets		_	2,505	2,505
Production costs capitalized		2,784	_	2,784
Write-down of capitalized costs		(341)	_	(341)
Transfer to inventory upon harvest		(1,477)	(1,107)	(2,584)
Balance, December 31, 2019	\$	1,243 \$	1,528 \$	2,771
Unrealized gain on changes in fair value of biological assets		_	3,989	3,989
Production costs capitalized		2,640	_	2,640
Transfer to inventory upon harvest		(3,011)	(4,053)	(7,064)
Balance, June 30, 2020	\$	872 \$	1,464 \$	2,336

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

The Company measures its biological assets at their fair values less estimated costs to sell. This is determined using a model which estimates the expected harvest yields in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price per gram, waste and also for any additional costs to be incurred, such as post-harvest cost.

The following significant unobservable inputs, all of which are classified as level three on the fair value hierarchy, were used by management as part of this model:

- Estimated selling price per gram calculated as the expected approximate future per gram selling prices of the Company's cannabis products. With no extensive history of sales, the Company evaluated industry data which is expected to closely approximate the Company's expected selling prices.
- Stage of growth represents the weighted average number of weeks out of the estimated week growing cycle that biological assets have reached as of the measurement date based on historical experience. The Company accretes fair value on a straight-line basis according to the stage of growth and estimated costs to complete cultivation.
- Yield by plant represents the expected number of grams of finished cannabis inventory which are expected to be
 obtained from each harvested cannabis plant based on historical experience.

The inter-relationship between these aforementioned unobservable inputs and the fair-value of the biological assets is such that the carrying value of the biological assets as at June 30, 2020 and December 31, 2019 would increase (decrease) if any of these inputs were to be higher (lower).

Other unobservable, level three inputs into the biological asset model include estimated post harvest costs, costs to complete and wastage. These additional level three inputs are not considered to be significant inputs.

The following table quantifies each significant unobservable input, and provides the impact of a 10% increase or decrease in each input would have on the fair value of biological assets:

	As at June 30, 2020	As at December 31, 2019	Impact of 10% change as at June 30, 2020	Impact of 10% change as at December 31, 2019
Estimated net selling price per gram (1)	\$3.18 to \$7.41	\$1.50 to \$6.29	\$ 558	\$ 466
Estimated stage of growth	8 to 9 weeks	8 to 9 weeks	\$ 537	\$ 163
Estimated yield of agricultural produce by plant (2)	46 to 98 grams	70 to 75 grams	\$ 264	\$ 303

- (1) The estimated net selling prices per gram is based on the negotiated distribution selling prices which exclude duties but included an estimate for the selling price of trim as at December 31, 2019 collected as part of the harvesting process which may have value in the oil production process.
- (2) The estimated yield varies based on the Company's different cannabis strains.

The Company's estimates are, by their nature, subject to change. Changes in the significant assumptions described will be reflected in future changes in the gain or loss on biological assets. There were no changes between fair value hierarchy levels.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

8. INVENTORY

The Company's inventory assets include the following as of June 30, 2020 and December 31, 2019:

			Hemp and Hemp	As at
	_	Dried Cannabis	Derived Products	June 30, 2020
Raw Materials and Packaging	\$	3,488 \$	1,344	\$ 4,832
Work-in-progress		4,756	2,599	7,355
Finished Goods	_	1,007	660	1,667
Total Inventory	\$	9,251 \$	4,603	\$ 13,854

	Dried Cannabis	Hemp and Hemp Derived Products	As at December 31, 2019
Raw Materials	\$ _	\$ 1,566	\$ 1,566
Work-in-progress	2,041	2,442	4,483
Finished Goods	518	735	1,253
Packaging and Supplies	805	161	966
Total Inventory	\$ 3,364	\$ 4,904	\$ 8,268

9. INVESTMENTS IN ASSOCIATES

The carrying value of investments in associates consist of:

		Balance,	Share of net	Foreign		Balance,
	Note	December 31, 2019	income (loss) (1)	exchange gain	_Impairment_	June 30, 2020
QuebecCo	9 [a]	2,191	3	_	_	2,194
Epican Medicinals Ltd.	9 [b]	2,727	(151)	506	(3,082)	_
		4,918	(148)	506	(3,082)	2,194

⁽¹⁾ Represents an estimate of the Company's share of net loss based on the latest available information of each investee.

[a] Investment in QuébecCo

The Company holds 2,001,134 Class A share of QuébecCo representing a 49.99% interest. QuébecCo holds a property located in the City of Salaberry-de-Valleyfield, Québec with a carrying value of \$4,002 and negligible liabilities.

[b] Investment in Epican Medicinals Limited ("EML")

During the six months ended June 30, 2020, the Company recognized an asset-specific impairment of its investment in EML of \$3,082 (\$nil for the three months ended June 30, 2020, and three and six months ended June 30, 2019) due to changing market conditions in Jamaica and the COVID-19 pandemic. On May 25, 2020, the Company sold its interest in EML to another shareholder of EML for a nominal amount. Upon completion of the disposition, EML repaid \$258 of a \$707 loan owing by EML to the Company as at the date of the sale and issued the Company a promissory note for the balance of \$449 included in other assets.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

10. OTHER ASSETS

A summary of other assets is presented as follows:

	As at June 30, 2020	As at December 31, 2019
Deposit per Hydro-Quebec contribution agreement	5,681	5,681
Investments in Califormulations and QuebecCo	3,887	3,887
Term deposits held as collateral	1,800	1,800
Deposits related to facility construction and operational readiness	830	690
Term deposits not held as collateral	200	292
Accrued interest receivable	81	60
Other	541	68
	13,020	12,478
Less: Current portion	(627)	(534)
	12,393	11.944

11. LEASES

Below is a summary of the activity related to the Company's lease liabilities:

Lease liabilities, December 31, 2019	\$ 3,545
Additions	1,709
Interest on lease liabilities	248
Interest payments on lease liabilities	(248)
Principal payments on lease liabilities	(169)
Foreign exchange differences	2
Lease liabilities, June 30, 2020	\$ 5,087
Current portion lease liabilities, June 30, 2020	\$ 858
Long-term portion lease liabilities, June 30, 2020	\$ 4,229

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

The Company received certain immaterial rent deferrals arising from conditions created by COVID-19 from one of its landlords. The Company applied the practical expedient under IFRS 16 not to account for the rent deferral as a modification to the Company's lease liabilities, however the Company's lease obligation as at June 30, 2020 was updated to account for the deferral of certain rent payment obligations.

12. SHARE CAPITAL

Issued capital

- a) During the six months ended June 30, 2020, a total of 847,600 shares of the Company were issued as a result of previously issued and outstanding options of the Company that were exercised at a weighted average exercise price of \$0.50 per option, for aggregate gross proceeds of \$424 (six months ended June 30, 2019 369,933 shares exercised at a weighted average exercise price of \$0.86 per option, for aggregate gross proceeds of \$319).
- b) During the six months ended June 30, 2020, a total of 500,500 shares of the Company were issued as a result of 500,500 previously issued and outstanding warrants of the Company that were exercised at a weighted average exercise price of \$0.38 per option, for aggregate gross proceeds of \$191 (six months ended June 30, 2019 5,105,411 warrants exercised at a weighted average exercise price of \$2.19 per warrant, for aggregate gross proceeds of \$11,206).
- c) During the six months ended June 30, 2020, a total of 27,174 shares of the Company were issued as a result of 27,174 previously issued and outstanding equity settled restricted share units ("RSU's") of the Company that were previously issued at a fair value of \$2.76 per RSU. There are no cash proceeds related to RSUs.
- d) During the six months ended June 30, 2020, a total of 24,691 shares of the Company were issued as a result of 24,691 previously issued and outstanding convertible share units of the Company that were previously issued at a fair value of \$4.05 per convertible share units. There are no cash proceeds related to convertible share units.
- e) On April 14, 2020, the Company issued a total of 6,025,042 shares to a consultant of the Company to settle accounts payable of \$1,626.
- f) On April 17, 2020, the Company completed a bought deal financing of 20,536,700 units and 10,268,350 warrants at a price of \$0.28 for aggregated proceeds of \$5,750. Each unit is comprised of one common share and one-half of one common share purchase warrant of the Company with value of the warrant being calculated using the Black Scholes valuation approach of \$0.04 per half warrant. Each full warrant entitles the holder to purchase one common share of the Company at an exercise price of \$0.38 for a period of 36 months from the date they were received on April 27, 2020. In addition, 1,232,202 broker warrants of the Company were issued to the underwrite in this bought deal; each broker warrant is exercisable at a price of \$0.38 per share for a period of 36 months from April 27, 2020 into one common share of the Company.
- g) On April 30, 2020, the Company issued a total of 833,333 shares with a value of \$250 to a former employee in respect of severance.
- h) On June 12, 2020, the Company completed a bought deal financing of 43,125,000 units and 43,125,000 warrants at a price of \$0.40 for aggregated proceeds of \$17,250. Each unit is comprised of one common share and one common share purchase warrant of the Company with value of the warrant being calculated using a market price approach of \$0.09 per warrant. Each warrant entitles the holder to purchase one common share at an exercise price of \$0.50 for a period of 48 months from the date they were received on June 12, 2020.

13. CONTRIBUTED SURPLUS

[a] Share based payments

The Company's Employee Stock Option Plan (the "ESOP") is administered by the Board of Directors of the Company which establishes exercise prices, at not less than the market price at the date of grant, and expiry dates, which have been set at three years from issuance. Options remain exercisable in increments with one third being exercisable on each of the first, second and third anniversaries from the date of the grant, except as otherwise approved by the Board of Directors.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

Under the ESOP, the Board of Directors may grant options, alone or in combination with other plans, of up to 10% of the common shares outstanding at the time of the grant for a term not exceeding five years. The exercise price of the options under the ESOP is fixed by the Board of Directors of the Company at the time of the grant at the market price of the common shares, subject to all applicable regulatory requirements. For the three and six months ended June 30, 2020, the Company recorded \$1,442 and \$3,595 respectively, in non-cash share-based compensation expense pursuant to the grant of stock options (three and six months ended June 30, 2019 - \$4,378 and \$7,736, respectively).

The following is a summary of the changes in the Company's ESOP options:

	For the six mo June 30,		For the year ended December 31, 2019		
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price	
Outstanding - beginning of period	17,897,599	3.24	12,430,732	2.83	
Granted	2,749,000	0.37	7,172,000	3.73	
Exercised	(847,600)	0.50	(506,933)	0.85	
Cancelled/Expired	(3,043,599)	2.22	(1,198,200)	2.91	
Outstanding, end of period	16,755,400	3.09	17,897,599	3.24	
Exercisable, end of period	6,359,995	3.47	5,871,199	2.34	

Grant date	Options Outstanding #	Options Exercisable #	Exercise Price \$	Average remaining contractual life of outstanding options in years
October 2, 2017 - January 12, 2018	1,972,400	1,516,000	\$1.15 - \$1.65	0.26 - 0.54
March 28, 2018	3,799,000	2,540,667	\$3.65	0.74
June 25, 2018 - December 14, 2018	2,093,333	793,329	\$3.08 - \$6.91	2.99 - 3.46
January 8, 2019 - August 21, 2019	5,525,667	1,510,000	\$2.67 - \$5.13	3.53 - 4.15
November 18, 2019	771,000	-	\$0.83	4.39
March 3, 2020 - May 28, 2020	2,594,000	-	\$0.37 - \$0.51	4.70 - 4.91
Balance, June 30, 2020	16,755,400	6,359,995	•	2.77

In determining the amount of share-based compensation, the Company uses the Black-Scholes option pricing model to establish the fair value as at the grant date of options granted. Stock options granted during the respective periods highlighted below were fair valued based on the following weighted average assumptions:

	Averages for the six months ended June 30, 2020	Averages for the year ended December 31, 2019
Risk-free interest rate	0.54%	1.55%
Expected dividend yield	Nil	Nil
Expected annualized volatility	82.08%	83.04%
Expected life of options (years)	3.50	3.50
Black-Scholes value of each option	\$0.13	\$2.04

Volatility was estimated by using the historical volatility of the Company and other companies that the Company considers comparable that have trading and volatility history. The expected life of the options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the expected life of the options is indicative of future trends, which may also not necessarily be the actual outcome. The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free rate was based upon the Canada government bonds with a remaining term equal to the expected life of the options.

Weighted

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

[b] Reserve for warrants

The following table reflects the continuity of warrants:

As at June 30, 2020, the following warrants were outstanding:

Issuance of warrants in connection with debt

Balance, December 31, 2019

Expiry Date	Exercise Price	Number of Warrants
	\$	#
October 2, 2020	3.00	130,250
February 28, 2021	3.00	34,477,515
April 19, 2021	9.00	12,592,500
June 26, 2021	9.50	1,955,000
December 19, 2022	1.00	20,607,500
December 20, 2022	1.00	7,000,000
April 1, 2023	0.39	3,000,000
April 13, 2023	0.39	1,500,000
April 27, 2023	0.38	11,000,552
May 27, 2024	0.50	500,000
June 12, 2024	0.50	45,712,500
		138,475,817

7,000,000

91,855,628

1.00

4.02

[c] Restricted share units

Under the Company's Restricted Share Unit Plan ("RSU Plan"), restricted share units may be granted up to a fixed maximum of 5,000,000 common shares, which entitle the holder to receive one common share without payment of additional

758

64,415

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

consideration at the end of the restricted period, as determined by the Board of Directors of the Company at the time of the grant. The RSU's vest in tranches based on certain performance conditions being met, with share-based compensation expense being recognized from grant to the expected performance completion date.

At June 30, 2020, 2,427,174 (December 31, 2019 – 54,348) shares of the Company were reserved for issuance under the RSU Plan. For the three and six months ended June 30, 2020, the Company recorded \$207 and \$259, respectively in non-cash stock-based compensation related to restricted share unit compensation (three and six months ended June 30, 2019 - \$29 and \$52, respectively).

	June 30, 2	2020	December 31, 2019		
	Number of Units	Weighted _Fair Value_	Number ofUnits	Weighted Fair Value	
Outstanding - beginning of period	54,348	2.76	_	-	
Granted	2,550,000	0.27	54,348	2.76	
Exercised	(27,174)	2.76	_	-	
Forfeited	(150,000)	0.27		_	
Outstanding, end of period	2,427,174	0.30	54,348	2.76	

The accounting fair value of the equity settled RSUs as at the grant date is calculated using the number of RSU's expected to be earned multiplied by the grant date fair market value of a share of the Company's stock. Each reporting period, the number of RSU's that are expected to be earned is re-determined and the "fair value" of these RSU's is amortized over the remaining requisite period less amounts previously recognized.

14. SUPPLEMENTARY CASH FLOW INFORMATION

The changes in non-cash working capital items are as follows:

	For the three months ended			onths ended	For the six mo	onths ended
		June 30, 2020		June 30, 2019	June 30, 2020	June 30, 2019
Prepaid expenses	\$	629	\$	(2,282)\$	(191) \$	(2,680)
Harmonized sales tax receivable		20		(3,555)	6,007	(481)
Accounts receivable		(1,203)		(433)	(1,168)	(1,571)
Capitalized cost of biological assets		2,284		(7)	3,382	20
Inventory		(3,557)		(264)	(6,910)	(9)
Other current assets		(129)		(1,951)	(237)	(1,972)
Other assets		(534)		(4,585)	(449)	(20,367)
Accounts payable and accrued liabilities		1,677		(301)	(102)	2,547
Deferred revenue		135		<u> </u>	135	
Total	\$	(678)	\$	(13,378) \$	467 \$	(24,513)

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

15. COMMITMENTS AND CONTINGENCIES

The Company has the following gross contractual obligations as at June 30, 2020, which are expected to be payable in the following respective periods:

	Contractual cash flows											
	Carrying amount	Total	2020	2021	2022	2023	2024	Thereafter				
	\$	\$	\$	\$	\$	\$	\$	\$				
Accounts payable and accrued												
liabilities	34,382	34,664	32,672	1,992	-	-	-	-				
Loans (1)	37,933	49,587	2,986	46,601	-	-	-	-				
Lease liabilities	5,087	8,822	445	837	771	627	612	5,530				
Commitments related to construction												
(2)	-	631	631	-	-	-	-	-				
Contingent consideration payable	101	160	-	-	160	-	-	-				
Total contractual obligations	77,503	93,864	36,734	49,430	931	627	612	5,530				

- (1) Contractual cash flows include interest payable until the maturity date for the Senior Loan and Revolver Loan amounts outstanding as at June 30, 2020. This table does not include additional loan advance completed subsequent to June 30, 2020. Refer to Notes 4 and 20.
- (2) Payables related to construction activities that have been incurred are included in accounts payable and accrued liabilities whereas amounts yet to be incurred have no carrying amount as at June 30, 2020 but have been committed and disclosed as contractual cash flows expected in fiscal year 2020.

[a] Construction agreements

The Company has entered into contracts to facilitate the construction of its facilities in Hamilton, Ontario and Salaberry-de-Valleyfield, Québec with various vendors. Pursuant to some of these agreements, as at June 30, 2020, the Company has letters of credit in the amount of \$1,800 which may be drawn upon in the event of material breaches of the respective agreements. These letters of credit bear conventional rates of interest partially offset by the interest earned on guaranteed investment certificates ("GIC") securing the letters as collateral. The Company has pledged corresponding GICs as collateral, which has been recorded in other assets. As at June 30, 2020, there have been no breaches and no amounts have been drawn on the letters of credit. As at June 30, 2020, the Company has outstanding deposits on construction related activities of \$830 (December 31, 2019 – \$690) also included in other assets.

The Company has also entered into escrow agreements in prior years with its construction partners in Ontario and in Québec and as such \$8,578 was included in restricted cash at December 31, 2019. During the six months ended June 30, 2020, the Company paid \$8,359 to the construction partners leaving a balance of \$219 in restricted cash as at June 30, 2020.

[b] Other contractual commitments

The lease for the office space of the Company's headquarters required the issuance of a letter of credit in the amount \$350, which may be drawn upon by the landlord in the event of a material breach of the agreement. As at June 30, 2020, there have been no breaches and no amounts have been drawn upon this letter of credit.

The Company has also entered into certain agreements for equipment and services that allow for deferred payment terms and/or the inclusion of permitted subordinated liens on personal property, per the Senior Loan agreement, associated with the equipment located at both the Hamilton and the Quebec facilities should there be any material breaches of the agreements. As at June 30, 2020, there have been no breaches of the respective agreements.

[c] Claims and Litigation

From time to time, the Company and/or its subsidiaries may become defendants in legal actions and the Company intends to defend itself vigorously against all legal claims. The Company is subject to certain employment related claims by former employees for which provisions have been recognized only to the extent that they are likely to result in future economic outflows in accounts payable and accrued liabilities. The Company has also been subject to a claim by former warrant holders for approximately \$1,250 and a separate claim for a customer in Europe for approximately \$2,100. No provision in relation to these claims has been recognized as the Company estimates that it is more likely than not that a present obligation does not exist that will result in a payment to be made by the Company for these claims. Other than the claims previously

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

described, the Company is not aware of any other material or significant claims against the Company.

16. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

[a] Fair values

The Company's financial instruments were comprised of the following as at June 30, 2020: cash and cash equivalents; restricted cash; refundable sales tax receivable; trade receivables; due from related parties; certain other investments; certain other current assets; accounts payable and accrued liabilities; loans and contingent consideration.

The fair values of the financial assets and financial liabilities are determined at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The assumption for the instruments recorded at amortized costs that the instruments' fair values approximate their carrying amounts is largely due to the short-term maturities of these instruments.

[b] Fair value hierarchy

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value.

During the three and six months ended June 30, 2020, there were no transfers of amounts between levels (three months ended December 31, 2019 – none).

[c] Management of risks arising from financial instruments

[i] Market risk

All foreign currencies shown in this note are also presented in thousands.

Foreign currency risk

Foreign currency risk arises due to fluctuations in the fair value or cash flows of financial instruments due to changes in foreign exchange rates. As at June 30, 2020, a portion of the Company's financial assets and liabilities held in US dollars ("USD"), Polish Zloty ("PLN") and European Euros ("EUR") which consisted of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities, lease liabilities, loans, and other assets. The Company's objective in managing its foreign currency risk is to minimize its net exposure to foreign currency cash flows by transacting, to the greatest extent possible, with third parties in the functional currency. The Company is exposed to currency risk in other comprehensive income, relating to foreign subsidiaries which operating in a foreign currency. The Company has not used foreign exchange contracts to hedge its exposure to foreign currency cash flows for the three months ended June 30, 2020 as management has determined that this risk is not significant at this time. The Company is exposed to unrealized foreign exchange risk through its accounts payable and accrued liabilities. As at June 30, 2020, a 10% change in the foreign exchange rate would result in an unrealized gain or loss of approximately \$1,709.

Interest rate risk

The Company's exposure to interest rate risk relates to any investments of surplus cash as the Company's debt is fixed at a prescribed rate. The Company may invest surplus cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. As at June 30, 2020, the Company had term deposits of \$2,000 bearing interest between 1.00% and 2.00% (December 31, 2019 - \$2,000, bearing interest between 1.60% and 3.05%). The Company also has \$219 in restricted cash held in trust related to the Valleyfield and Hamilton construction projects and

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

earning a conventional rate of interest from a reputable top tier Canadian bank.

[ii] Credit risk

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit-related losses in the event of non-performance by the counterparties.

The carrying amount of cash and cash equivalents, trade receivable, refundable sales tax receivable, due from related parties, prepaids and deposits, and other assets represents the maximum exposure to credit risk as at June 30, 2020. The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors. Credit risk is mitigated by entering into sales contracts with stable, creditworthy parties and through frequent reviews of exposures to individual entities.

The Company assesses the credit risk of trade receivables by evaluating the aging of trade receivables based on the invoice date. The carrying amount of trade receivables is reduced through the use of an allowance account and the amount of the loss is recognized in the consolidated statements of loss and comprehensive loss. When a trade receivable balance is considered uncollectible, it is written off against the allowance for expected credit losses. Subsequent recoveries of amounts previously written off are credited against operating expenses in the consolidated statements of loss and comprehensive loss. As at June 30, 2020, the Company's trade receivables are primarily concentrated in Canada with the exception of \$712 in Europe. The Company had two customers whose balances individually were greater than 10% of total trade receivables as at June 30, 2020 (December 31, 2019 – one customer).

The following tables set forth details of trade receivables, including aging of trade receivables that are not overdue, as well as an analysis of overdue amounts and related allowance for doubtful accounts:

	June 30, 2020	December 31, 2019
	\$	\$
Total trade receivables	3,350	2,254
Less allowance for expected credit losses	(694)	(766)
Total trade receivables, net	2,656	1,488
Of which		
Current	2,578	1,053
31-90 days	22	372
Over 90 days	750	829
Less allowance for expected credit losses	(694)	(766)
Total trade receivables, net	2,656	1,488

[iii] Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements in relation to its current cash balances, maturity schedules and internal budgets. Refer to Note 15 – Commitments and Contingencies.

17. SEGMENTED INFORMATION

The Company's business activities are conducted through one operating segment which consists of the production and distribution of cannabis and related products. Segment performance is based by region.

[i] Revenue, gross profit and select expenses by region is as follows

For the three months ended June 30, 2020, the Company had one customer that accounted for 28% of total revenue (three months ended June 30, 2019 – one customer that accounted for 15% of total revenue). For the six months ended June 30, 2020, the Company had one customer that accounted for 17% of total revenue (six months ended June 30, 2019 – two customers that accounted for 12% and 10% of total revenue).

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

		For the three months ended June 30, 2020					For th	x months ne 30, 202	led
		Europe		North America		Total	Europe	North America	Total
Revenue	\$_	2,112	\$	2,713	\$	4,825	\$ 4,507	\$ 3,377	\$ 7,884
Gross profit	\$_	1,089	\$	237	\$	1,326	\$ 2,574	\$ 458	\$ 3,032
Operating expenses, excluding stock- based compensation, depreciation and amortization	\$	1,529	\$	6,740	\$	8,269	\$ 3,630	\$ 17,414	\$ 21,044
Share based compensation	s _		\$	1,657	\$	1,657	\$ 	\$ 4,127	\$ 4,127
Depreciation and amortization	\$_	369	\$	912	\$	1,281	\$ 913	\$ 2,087	\$ 3,000
Non-operating income	\$_	159	\$	(268)	\$	(109)	\$ (418)	\$ (57,931)	\$ (58,349)
Net loss	\$_	(435)	\$	(9,340)	\$	(9,775)	\$ (2,109)	\$ (81,102)	\$ (83,211)

		For th	For th	six months end une 30, 2019	ed		
	_	Europe	North America	Total	Europe	North America	Total
Revenue	\$	2,878 \$	\$	2,896	\$ 5,281	\$ 	5,301
Gross profit (loss)	\$_	1,975 \$	(18)\$	1,957	\$ 3,126	\$ 198 \$	3,324
Operating expenses, excluding stock-base compensation, depreciation and amortization	d \$	1,758 \$	11,445 \$	13,203	\$ 3,072	\$ 22,242 \$	25,314
Share based compensation	\$_	\$	4,433 \$	4,433	\$ _	\$ 7,852 \$	7,852
Depreciation and amortization	\$_	434 \$	304 \$	738	\$ 715	\$ 584 \$	1,299
Non-operating income	\$_	(611) \$	361 \$	(250)	\$ (562)	\$ 1,052 \$	490
Net loss	S	(764) \$	(15.839) \$	(16,603)	\$ (1.266)	\$ (29,428) \$	(30,694)

[ii] Property, plant and equipment, net is domiciled as follows

	June 30, 2020			December 31, 2019
North America	\$	204,720	\$	232,827
Europe		4,087		4,206
	\$	208,807	\$	237,033

[iii] Intangible assets and goodwill, net are domiciled as follows

	 June 30, 2020	_	December 31, 2019
North America	\$ 3,801	\$	5,032
Europe	15,409		15,088
	\$ 19,210	\$	20,120

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

18. CAPITAL MANAGEMENT

The Company's objective is to maintain sufficient capital base to maintain investor, creditor and supplier confidence and to sustain future development of the business and provide the ability to continue as a going concern (See Note 2[i] – Going Concern). Management defines capital as the Company's shareholders' equity and loans. The Board of Directors of the Company does not establish quantitative return on capital criteria for management but rather promotes year over year sustainable profitable growth. The Company currently has not paid any dividends to its shareholders. As at June 30, 2020, total managed capital was comprised of share capital and loans of \$485,763 (December 31, 2019 - \$446,084), contributed surplus of \$104,326 (December 31, 2019 - \$95,763), and reserve for foreign translations of \$164 (December 31, 2019 – \$2,241). There were no changes in the Company's approach to capital management during the three and six months ended June 30, 2020 (three and six months ended June 30, 2019 – no changes).

19. OPERATING EXPENSES

The following table presents stock-based compensation, depreciation and amortization by function:

	Three mont	hs ended	Six months ended				
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019			
Cost of sales related to inventory production	\$ 958 \$	696	\$ 2,270\$	1,204			
Sales and marketing expenses	284	567	692	1,004			
Research and development expenses	169	373	414	712			
General and administrative expenses	1,527	3,535	3,751	6,231			

As described in Note 3(b), during the three months ended June 30, 2020, the Company received benefits under the CEWS and recognized the receipt of cash against the related personnel costs which amounted to \$987, of which, \$96 related to sales and marketing expenses, \$45 related to research and development expenses and \$342 in general and administrative expenses. The remainder of the benefits were allocated to inventory production related personnel. No subsidies were received during the three and six months ended June 30, 2019.

20. EVENTS AFTER THE REPORTING PERIOD

- a) The Company obtained gross debt proceeds of \$3,000 on July 7, 2020 in accordance with the modification of its Revolver Loan (See description in Note 4).
- b) On August 3, 2020 the Company was named as a defendant in a litigation matter commenced in the United States District Court for the Middle District of Georgia relating to its minority investment in a US based beverage incubation business, seeking, among other things, unquantified compensatory damages and injunctive relief. No provision in relation to this claim has been recognized as the Company estimates that it is more likely than not that a present obligation does not exist that will result in a payment to be made by the Company for this claim and the Company intends to vigorously defend the matter.